Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 100,000 Shares of Company Stock

Key Points

• Director Jack Schuler bought 100,000 Biodesix shares at an average of $10.02, investing about $1 million and increasing his position by 17.99% to 655,810 shares.
• Biodesix reported quarterly EPS of -$0.75, matching estimates, but revenue of $24.04 million came in below the $27.48 million forecast; the company also posted a negative net margin.
• Analysts’ average rating is “Moderate Buy,” with a $34.20 consensus price target, while forecast cuts and an investor investigation add uncertainty.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler purchased 100,000 shares of the firm's stock in a transaction dated Tuesday, November 10th. The stock was purchased at an average cost of $10.02 per share, for a total transaction of $1,002,000.00. Following the acquisition, the director owned 655,810 shares of the company's stock, valued at approximately $6,571,216.20. This trade represents a 17.99% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Price Performance

Shares of BDSX stock traded up $0.14 on Thursday, reaching $10.26. The company's stock had a trading volume of 81,644 shares, compared to its average volume of 488,181. The company has a market capitalization of $113.81 million, a P/E ratio of -3.73 and a beta of 0.65. Biodesix, Inc. has a 12-month low of $5.26 and a 12-month high of $31.97. The stock's 50 day simple moving average is $24.57 and its 200-day simple moving average is $18.88. The company has a quick ratio of 2.85, a current ratio of 2.96 and a debt-to-equity ratio of 5.43.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The business had revenue of $24.04 million during the quarter, compared to analyst estimates of $27.48 million. Biodesix had a negative net margin of 25.74% and a negative return on equity of 442.34%. As a group, equities analysts predict that Biodesix, Inc. will post -2.95 earnings per share for the current fiscal year.

Key Biodesix News

These are some of the BDSX news items that stood out recently:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $34 price target despite lowering its forecasts, providing a potentially supportive analyst view. HC Wainwright Has Lowered Expectations for Biodesix Stock Price
• Negative Sentiment: HC Wainwright cut estimates across 2026 and 2027, including FY2026 EPS to a loss of $3.13 from $2.72 and FY2027 EPS to a loss of $2.18 from $1.57. The sizable revisions point to expectations of deeper losses and could weigh on investor sentiment.
• Negative Sentiment: Johnson Fistel launched an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information, following the stock’s sharp decline on Nov. 6. The inquiry is not a finding of wrongdoing, but it adds legal and reputational uncertainty. Johnson Fistel Announces Biodesix Investor Investigation

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Weiss Ratings upgraded Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 8th. Canaccord Genuity Group upped their target price on Biodesix from $27.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. HC Wainwright reduced their price target on shares of Biodesix from $38.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday. TD Cowen reissued a "buy" rating and set a $40.00 price target (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. Finally, Lake Street Capital lowered their price objective on shares of Biodesix from $40.00 to $30.00 and set a "buy" rating for the company in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $34.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC bought a new stake in Biodesix during the 2nd quarter valued at $15,296,000. Walleye Capital LLC purchased a new position in shares of Biodesix in the second quarter valued at about $1,679,000. Stempoint Capital LP purchased a new position in shares of Biodesix in the first quarter valued at about $1,015,000. GSA Capital Partners LLP purchased a new position in shares of Biodesix in the second quarter valued at about $1,060,000. Finally, BlackRock Inc. bought a new position in shares of Biodesix during the second quarter valued at about $970,000. 20.96% of the stock is owned by institutional investors.

About Biodesix

Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.